Basic Information
| LncRNA/CircRNA Name | LINC00963 |
| Synonyms | NA |
| Region | GRCh38_9:129483451-129513686 |
| Ensemble | ENSG00000204054 |
| Refseq | NR_038955 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | melanoma |
| ICD-0-3 | NA |
| Methods | qPCR, Dual luciferase reporter assay |
| Sample | melanoma tissues, cell lines(A375, A2508) |
| Expression Pattern | up-regulated |
| Function Description | upregulated level of LINC00963 in melanoma tissueswas observed. And high expression of LINC00963 predicts poor prognosis in patients with melanoma. Functionalinvestigation indicated that LINC00963 knockdown dramatically suppressed melanoma cell proliferation, migration and invasion. Upregulated LINC00963 led to elevated expression of NACC1 throughinhibiting miR-608. |
| Pubmed ID | 30180950 |
| Year | 2018 |
| Title | Upregulation of LINC00963 facilitates melanoma progression through miR-608/NACC1 pathway and predicts poor prognosis. |
External Links
| Links for LINC00963 | GenBank HGNC NONCODE |
| Links for melanoma | OMIM COSMIC |